Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
18.03
-0.76 (-4.04%)
May 14, 2026, 11:45 AM EDT - Market open
Summit Therapeutics Employees
Summit Therapeutics had 265 employees as of December 31, 2025. The number of employees increased by 106 or 66.67% compared to the previous year.
Employees
265
Change (1Y)
106
Growth (1Y)
66.67%
Revenue / Employee
n/a
Profits / Employee
-$4,551,309
Market Cap
13.99B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 265 | 106 | 66.67% |
| Dec 31, 2024 | 159 | 54 | 51.43% |
| Dec 31, 2023 | 105 | 28 | 36.36% |
| Dec 31, 2022 | 77 | -33 | -30.00% |
| Dec 31, 2021 | 110 | 29 | 35.80% |
| Dec 31, 2020 | 81 | 11 | 15.71% |
| Dec 31, 2019 | 70 | 9 | 14.75% |
| Dec 31, 2018 | 61 | -15 | -19.74% |
| Dec 31, 2017 | 76 | 36 | 90.00% |
| Dec 31, 2016 | 40 | 3 | 8.11% |
| Dec 31, 2015 | 37 | 14 | 60.87% |
| Dec 31, 2014 | 23 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Genmab | 3,088 |
| Jazz Pharmaceuticals | 2,890 |
| Incyte | 2,844 |
| Ionis Pharmaceuticals | 1,402 |
| Axsome Therapeutics | 1,220 |
| Ascendis Pharma | 1,189 |
| Exelixis | 1,077 |
| Madrigal Pharmaceuticals | 915 |
SMMT News
- 10 days ago - Summit Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 10 days ago - Summit Therapeutics price target lowered to $23 from $30 at H.C. Wainwright - TheFly
- 12 days ago - Summit Therapeutics falls -23.7% - TheFly
- 13 days ago - Summit Therapeutics falls -27.4% - TheFly
- 13 days ago - Summit Therapeutics price target lowered to $16 from $17 at Piper Sandler - TheFly
- 13 days ago - Summit Therapeutics price target lowered to $31 from $32 at Clear Street - TheFly
- 13 days ago - Summit Therapeutics reports Q1 adjusted EPS (15c), consensus (21c) - TheFly
- 13 days ago - Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026 - Business Wire